IBRX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$14.25median target· current $9.18 (+55.2%)4 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 123.46
EPS (TTM)$-0.970.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$9.73BMid cap
Valuation
- Forward P/E
- 123.46
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- 58.68
- EV/EBITDA
- -8.99
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- -120.4%
- Revenue growth YoY
- 93.9%
- Dividend yield
- —
- Beta
- 0.03
Last earnings
Aug 4, 2026 · Estimate $-0.09 · Reported $-0.08
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Immunitybio Inc
Company profileImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 3530 JOHN HOPKINS COURT, SAN DIEGO, CA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$9.73B
Shares outstanding$1.06B
52W high$12.43
52W low$1.95
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent